Current perspectives on cell-assisted lipotransfer for breast cancer patients after radiotherapy

Table 5 Demographics of patients who received radiotherapy extracted from the three studies (irradiated patients reconstructed with CAL vs. irradiated patients reconstructed with lipofilling)

First author	Age (y)	Preoperative BMI (kg/m²)	Tumour type	Type of reconstruction	Volume of fat graft (mL)	Follow-up (m) **	Volumetric persistence (%)
Irradiated patients reconstructed with CAL
Tissiani LAL ²⁰¹⁶
	55	24.2	LCI	LD + IMPL	45	49	-27.33
	47	25.4	Mucinous	LD + IMPL	92	45	68.17
	48	27.2	DCI	LD + IMPL	137	38	87.20
	41	27.5	DCIS	TRAM	147	37	276.51
	54	24.0	DCI	LD + IMPL	141	34	69.07
	44	23.5	DCI	LD + IMPL	117	33	31.97
	56	23.9	DCI	TRAM	111	33	99.79
	43	30.9	LCI	Seq-explantation	159	20	31.38
mean ± SD	48.5 ± 5.8	25.8 ± 2.6	-	-	118.6 ± 36.8	36.1 ± 8.7**	79.6 ± 89.0
Ito S ²⁰¹⁷
	56	21.1	NA	No	120	NA	NA
	56	25.3	NA	No	80	NA	NA
	46	18.4	NA	No	154	NA	NA
	34	19.8	NA	No	84	NA	NA
	53	22.3	NA	No	83	NA	NA
	52	24.4	NA	No	98	NA	NA
	41	19.7	NA	No	50	NA	NA
	45	19.7	NA	No	46	NA	NA
	50	21.6	NA	No	152	NA	NA
	35	20.1	NA	No	70	NA	NA
mean ± SD	46.8 ± 8.1	21.2 ± 2.2	-	-	93.7 ± 37.8	-	-
Jeon HJ ²⁰²¹
	35	20	DCI	LD	120	12	64.1
	46	22.9	DCI	TRAM	200	12	58.5
	36	30.1	DCI	LD	120	12	42.9
mean ± SD	39.0 ± 6.1	24.3 ± 5.2	-	-	146.7 ± 46.2	12	55.2 ± 11.0
Irradiated patients reconstructed with lipofilling
Tissiani LAL ²⁰¹⁶
	56	32.4	DCI	Seq-explantation	147	21	41.63
	69	25.9	DCIS	LD + IMPL	111	15	68.6
	38	24.1	DCI	LD + IMPL	108	13	70.23
	36	24.1	DCI	LD + IMPL	115	12	27.65
	49	24.9	DCIS	Seq-explantation	102	8	36.2
mean ± SD	49.6 ± 13.6	26.3 ± 3.5	-	-	116.6 ± 17.6	13.8 ± 4.8	48.9 ± 19.4
Jeon HJ ²⁰²¹
	44	22.8	DCI	LD	60	12	36.2
	55	23.6	DCIS	LD	160	12	33.5

CAL Cell-assisted lipotransfer, BMI Body mass index, LCI Lobular carcinoma invasive, DCI Ductal carcinoma invasive, DCIS Ductal carcinoma in situ, LD Latissimus dorsi flap, IMPL Implant, TRAM Transverse rectus abdominis myocutaneous flap, y Year, m Months, NA Not available. **P < 0.01

ISSN: 1477-7819